Trial Profile
A Multicenter, Randomized, Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of FTY720 in Patients With Acute, Noninfectious Intermediate, Posterior and Pan Uveitis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Corticosteroids
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 03 May 2014 New trial record